Craft

Zoetis

Stock Price

$181.3

2024-10-29

Market Capitalization

$82.1 B

2024-10-29

Revenue

$8.5 B

FY, 2023

Zoetis Summary

Company Summary

Overview
Zoetis (formerly known as Pfizer Animal Health) is an animal health company focusing on the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products and services. It offers parasiticides, vaccines, dermatology products, anti-infectives, medicated feed additives, and other pharmaceutical products, as well as biodevices, genetic tests, and animal health diagnostic solutions. The company commercializes products across eight core species: dogs, cats, horses, cattle, swine, poultry, fish, and sheep.
Type
Public
Status
Active
Founded
1952
HQ
Parsippany, NJ, US | view all locations
Website
https://www.zoetis.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Kristin Peck

    Kristin Peck, Chief Executive Officer and Board Member

  • Wetteny Joseph

    Wetteny Joseph, Executive Vice President and Chief Financial Officer

  • Heidi Chen

    Heidi Chen, Executive Vice President, General Counsel and Corporate Secretary, Business Lead of Human Health Diagnostics

  • Jeannette Ferran Astorga

    Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer

Operating MetricsView all

Countries

100

Q3, 2021

Floor Space, square feet

11.1M

FY, 2020

Product Lines

300

Q3, 2021

LocationsView all

68 locations detected

  • Parsippany, NJ HQ

    United States

    10 Sylvan Way

  • Buenos Aires, CABA

    Argentina

    Virrey Loreto 2477

  • Villa Adelina, Provincia de Buenos Aires

    Argentina

    Av. Fondo de la Legua 1171 2º Piso

  • Silverwater, NSW

    Australia

    PO Box 6066

  • Wien, Wien

    Austria

    Floridsdorfer Hauptstraße 1

  • Ottignies-Louvain-la-Neuve, Région Wallonne

    Belgium

    Rue du Laid Burniat 1

and 62 others

Zoetis Financials

Summary Financials

Revenue (Q3, 2024)
$2.4B
Gross profit (Q3, 2024)
$1.7B
Net income (Q3, 2024)
$692.0M
Cash (Q3, 2024)
$1.7B
Enterprise value
$87.0B

Footer menu